Overview

A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of PUR0200. In addition, the study will look at the blood levels of different doses of PUR0200 and their affect on lung function in COPD patients.
Phase:
Phase 1
Details
Lead Sponsor:
Pulmatrix Inc.
Collaborator:
Quotient Clinical